Terms: = Endocrine gland cancer AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID AND Treatment
87 results:
1. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial.
Kim SI; Joung JG; Kim YN; Park J; Park E; Kim JW; Lee S; Lee JB; Kim S; Choi CH; Kim HS; Lim J; Chung J; Kim BG; Lee JY
Gynecol Oncol; 2024 Mar; 182():7-14. PubMed ID: 38246047
[TBL] [Abstract] [Full Text] [Related]
2. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C; Derangère V; Gaudillière-Le Dain G; Huppe T; Rageot D; Ilie A; Vienot A; Borg C; Monnien F; Bibeau F; Truntzer C; Ghiringhelli F;
Oncoimmunology; 2024; 13(1):2294563. PubMed ID: 38169969
[TBL] [Abstract] [Full Text] [Related]
3. Identification of foxp3
Gong R; Chen X; Sun X; Zhang Y; Wang J; Yu Q; Lei K; Ren H
Am J Physiol Cell Physiol; 2024 Jan; 326(1):C294-C303. PubMed ID: 38047300
[TBL] [Abstract] [Full Text] [Related]
4. Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Katz MHG; Petroni GR; Bauer T; Reilley MJ; Wolpin BM; Stucky CC; Bekaii-Saab TS; Elias R; Merchant N; Dias Costa A; Lenehan P; Cardot-Ruffino V; Rodig S; Pfaff K; Dougan SK; Nowak JA; Varadhachary GR; Slingluff CL; Rahma O
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040420
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine.
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Jasiunaite E; Zvirblis T; Sileikis A
Int Immunopharmacol; 2023 Feb; 115():109722. PubMed ID: 37724957
[TBL] [Abstract] [Full Text] [Related]
6. The immune microenvironment after neoadjuvant therapy compared to upfront surgery in patients with pancreatic cancer.
Zwart ES; van Ee T; Doppenberg D; Farina A; Wilmink JW; Versteijne E; Busch OR; Besselink MG; Meijer LL; van Kooyk Y; Mebius RE; Kazemier G
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14731-14743. PubMed ID: 37587309
[TBL] [Abstract] [Full Text] [Related]
7. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian cancer (GEICO-89T/MINOVA Study).
Tavira B; Iscar T; Manso L; Santaballa A; Gil-Martin M; García García Y; Romeo M; Iglesias M; de Juan Ferré A; Barretina-Ginesta MP; Manzano A; Gaba L; Rubio MJ; de Andrea CE; González-Martín A
Clin Cancer Res; 2024 Jan; 30(1):176-186. PubMed ID: 37527007
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
9. Spontaneous Murine Model of Anaplastic Thyroid cancer.
Yan H; Ma Y; Zhou X; He Y; Liu Y; Caulin C; Wang L; Xu H; Luo H
J Vis Exp; 2023 Feb; (192):. PubMed ID: 36804915
[TBL] [Abstract] [Full Text] [Related]
10. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
[TBL] [Abstract] [Full Text] [Related]
11. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
[TBL] [Abstract] [Full Text] [Related]
12. Comprehensive immunoprofile analysis of prognostic markers in pancreaticobiliary tract cancers.
Kim JE; Kim H; Kim B; Chung HG; Chung HH; Kim KM; Kim SH; Jeong WK; Kim YK; Min JH; Heo JS; Han IW; Shin SH; Park HC; Yu JI; Park JO; Kim ST; Hong JY; Lee SH; Lee KH; Lee JK; Lee KT; Jang KT; Park JK
Cancer Med; 2023 Apr; 12(7):7748-7761. PubMed ID: 36650632
[TBL] [Abstract] [Full Text] [Related]
13. TGF-β2 antisense oligonucleotide enhances T-cell mediated anti-tumor activities by IL-2 via attenuation of fibrotic reaction in a humanized mouse model of pancreatic ductal adenocarcinoma.
Lee HK; Nam MW; Go RE; Koo J; Kim TH; Park JE; Choi KC
Biomed Pharmacother; 2023 Mar; 159():114212. PubMed ID: 36610224
[TBL] [Abstract] [Full Text] [Related]
14. Herpesvirus entry mediator regulates the transduction of Tregs via STAT5/foxp3 signaling pathway in ovarian cancer cells.
Shan Y; Zhang B; Chen L; Zhang H; Jiang C; You Q; Li Y; Han H; Zhu J
Anticancer Drugs; 2023 Jan; 34(1):73-80. PubMed ID: 35946515
[TBL] [Abstract] [Full Text] [Related]
15. The Effects of treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC).
Tulyte S; Characiejus D; Matuzeviciene R; Janiulioniene A; Radzevicius M; Zvirblis T; Sileikis A
Anticancer Res; 2022 Jun; 42(6):3067-3073. PubMed ID: 35641268
[TBL] [Abstract] [Full Text] [Related]
16. Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Hyung J; Lee H; Jin H; Lee S; Lee HJ; Gong G; Song TJ; Lee SS; Hwang DW; Kim SC; Jeong JH; Ryoo BY; Kim K; Yoo C
ESMO Open; 2022 Jun; 7(3):100484. PubMed ID: 35576696
[TBL] [Abstract] [Full Text] [Related]
17. Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma.
Gartrell RD; Enzler T; Kim PS; Fullerton BT; Fazlollahi L; Chen AX; Minns HE; Perni S; Weisberg SP; Rizk EM; Wang S; Oh EJ; Guo XV; Chiuzan C; Manji GA; Bates SE; Chabot J; Schrope B; Kluger M; Emond J; Rabadán R; Farber D; Remotti HE; Horowitz DP; Saenger YM
Oncoimmunology; 2022; 11(1):2066767. PubMed ID: 35558160
[TBL] [Abstract] [Full Text] [Related]
18. Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer.
Sasaki T; Nishiwada S; Nakagawa K; Nagai M; Terai T; Hokuto D; Yasuda S; Matsuo Y; Doi S; Sho M
Int J Clin Oncol; 2022 May; 27(5):948-957. PubMed ID: 35142963
[TBL] [Abstract] [Full Text] [Related]
19. Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma.
Spiliopoulou P; Spear S; Mirza H; Garner I; McGarry L; Grundland-Freile F; Cheng Z; Ennis DP; Iyer N; McNamara S; Natoli M; Mason S; Blyth K; Adams PD; Roxburgh P; Fuchter MJ; Brown B; McNeish IA
Mol Cancer Ther; 2022 Apr; 21(4):522-534. PubMed ID: 35131874
[TBL] [Abstract] [Full Text] [Related]
20. PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules.
Zhang Y; Chen X; Mo S; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):257-267. PubMed ID: 35037417
[TBL] [Abstract] [Full Text] [Related]
[Next]
